快要 飞的 《药股》 讨论区

葉芬

原帖由 kelvin234 于 6-11-2009 11:50 PM 发表
cvm为什么不在前天大起
没钱收票的结果..都压在ddr了,跌到像鬼酱...

玩投機時運氣也是很重要的因素之一。

kelvin234

我要快存钱买别的股了..
ddr这个应该需要几个月才能回到接近10远吧,希望股息给多点

葉芬

First Clinical Study of Investigational LEAPS-H1N1 Treatment Will Take Place at Johns Hopkins University School of Medicine

Written by Staff and Wire Reports   
Friday, 06 November 2009 00:00

One of several expected key news developments has been announced by CEL-SCI Corporation (NYSE Amex: CVM), today. An Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study involving the much talked about  L.E.A.P.S.™ H1N1 investigational therapy.

Johns Hopkins will host the study, which will be led by Principal Investigator Jonathan M. Zenilman, MD, Professor of Medicine, Johns Hopkins School of Medicine and Chief of Infectious Diseases Division, Johns Hopkins Bayview Medical Center. As previously announced, this initial study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.

The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical development program builds on CEL-SCI's pioneering work with its  L.E.A.P.S.™ technology in the context of H1N1. As previously discussed in this space by Dr. Daniel Zimmerman, inventor of the L.E.A.P.S.™ technology, the technology allows the Company to direct an immune response against specific disease epitopes. The technology's reach will go beyond the H1N1 space, into fields of treatment like rheumatoid arthritis since those responses can be designed to be directed at a great number of human diseases.

In the case of CEL-SCI's investigational LEAPS-H1N1 treatment, this involves non-changing regions of the H1N1 Pandemic Flu as well as the Avian Flu (H5N1), and the Spanish Flu.

"We are pleased that such a prestigious medical center has given clearance to proceed with this first study of our LEAPS-H1N1 treatment," said Geert Kersten, CEL-SCI's Chief Executive Officer. "Given the nature and severity of the virus, we are working diligently with our CRO and Johns Hopkins, and actively preparing submissions to the FDA, to support the fastest and most effective way to conduct clinical trials going forward for this unique investigational treatment."

In September, the company announced that the FDA had indicated that they could commence this study and scientists at the company have been working hard on various aspects of what is expected to be the first of several upcoming expedited steps to get this treatment authorized and out to those hospitalized patients who desperately need it.

In order for FDA to fully consider a next-stage clinical trial to evaluate LEAPS-H1N1 treatment of hospitalized patients with laboratory-confirmed H1N1 Pandemic Flu under an Exploratory IND, FDA has asked CEL-SCI to submit a detailed follow-up regulatory filing with extensive additional data.

President Obama's national emergency declaration due to the H1N1 pandemic gave Health and Human Services Secretary Kathleen Sebelius the authority to bypass federal rules in order to get treatments like this one to patients who may need them. Most recently, the FDA announced emergency use authorization for BioCryst's intravenous peramivir, an investigational antiviral drug, for use in adult and pediatric patients, even though the drug had not completed all of the normal steps required for approval. In fact, the drug is not technically yet approved by the FDA. Emergency use authorization for the product will last until the emergency declaration is terminated or until the FDA revokes the privilege.

"Many millions" of Americans have had swine flu so far, according to CDC Director Dr. Thomas Frieden and the number is growing, causing many hospitals to overflow with sick patients. “Vaccine production is much less predictable then we wish. We are nowhere near where we thought we’d be by now,” Friedan said. “As public health professionals, vaccination is our strongest tool. Not having enough of it is frustrating to all of us.”

As reported months ago, the growing pandemic of H1N1 has had members of the Obama administration working behind the scenes for months trying to keep the problem from cripling an already fragile economy.

Investors, who have sent the stock price up on the news, apparently also view the news as a much needed credibility boost in light of recent attacks by a single columnist. Company lawyers are reportedly "taking steps to correct the misleading attacks designed to help short the stock each time positive news is announced."

Despite those attacks, shares of the company have risen dramatically in the past few months and that trend is expected to continue as the company moves forward on several fronts, including a pending launch of Phase III trials for Multikine®, CEL-SCI's flagship cancer immunotherapeutic agent, which is being developed as a first-line standard of care cancer treatment.

Developing...

葉芬

http://vfcsstockhouse.blogspot.c ... s-hopkins-move.html


Friday, November 6, 2009
CVM: Cel Sci and Johns Hopkins Move Forward With LEAPS

Shortly after the market open on Friday, Cel Sci Corp issued a press release declaring that the company will commence a Clinical Study measuring the effectiveness of the company's LEAPS technology in the treatment of H1N1-hospitalized patients. According to the press release, blood will be drawn from the hospitalized patients and then the cells will be "activated" with the LEAPS-H1N1 treatment "in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol." [Quotes were taken directly from Friday's PR]

This study was expected, as the company informed investors in September that the FDA had given Cel Sci the 'go-ahead', but what is significant, in my opinion, is the fact that Johns Hopkins has jumped on board. Johns Hopkins University is one of the nation's most prestigious - especially in terms of the School of Medicine. The fact that an "Institutional Review Board" of Johns Hopkins University gave the clearance for the this clinical study to proceed - with the Johns Hopkins name attached to it -should give sceptical investors a 'warm & fuzzy' that there is some significant potential for LEAPS to become an effective treatment for H1N1 patients.

In short, Johns Hopkins is no joke and the institution gives instant credibility to any ongoing clinical study that they are willing to attach their name to. Does that mean that LEAPS is now a sure bet? No, but the Scientists and Doctors at Hopkins saw something, and that makes VFC more confident than ever that there is more potential to the LEAPS-H1N1 treatment than many have been willing to speculate.

With the study now ready to start, news and updates could come quick; it'll be worth watching the wires over the next few weeks, in my opinion.

What also struck me as somewhat odd was the timing of the PR. Usually - at least in my own experiences - news that would be construed as positive is released towards the beginning of the week, not on Friday, so that the stock could build some early-week momentum rather than have the good news forgotten about by the time trading resumes on Monday.

This is purely speculation on my part, but the timing of the PR has me interested in the possibility that additional news releases may be forthcoming from Cel Sci in the near future.

On another note, I've been asked for a few to comment on some recent blog postings regarding Cel Sci on TheStreet.com website. I'll just say this: I've only read what has been copied and pasted from those blog posts onto other boards because I don't follow 'TheStreet.com', nor their blogs, but I've seen nothing pertinent regarding the potential of Cel Sci or its products come from 'TheStreet.' What I have seen are articles that, in my opinion, support an ulterior agenda and look to incite suspicion rather than discuss the potential of the products.

VFC doesn't play that game.

Additionally, regarding the whole Multikine licensing deal with Byron for South Africa, I didn't invest in Cel Sci in anticipation of South African royalties. Cel Sci has Teva and Orient on board with Multikine and now Johns Hopkins on board with LEAPS H1N1 - all very established and well respected entities. As for Byron, it's a non issue, in my opinion. Someone has the rights to market Multikine in South Africa, and those rights could turn out to be very valuable if Multikine is deemed a success.

Things are just heating up for Cel Sci and a few games and distractions by the 'Big Boys' shouldn't deter investors from following the progression of the company.

The facts are these: The potential of LEAPS for H1N1 is real - Johns Hopkins just validated that fact - and Multikine is closer than ever to Phase III, judging by the progress being made at the Baltimore area manufacturing facility.

As always, this is just my opinion and each investor should do thier own DD and then invest based on that DD and their own comfort level for risk.

'Nuff Said, for now.

Disclosure: VFC is long CVM.

葉芬

Conference Nov 9th ~ 10th in Washington D.C.


http://www.gtcbio.com/userAgenda.aspx?id=166

kelvin234

超过1.20了...应该不少人赚到吧.芬姐赚多少??

葉芬

1.22  +0.20(19.48%)
Nov 6 - Close

After Hours  1.24
Change  +0.02 (1.64%)                        


下星期一CVM應該會是很不錯的一天。

[ 本帖最后由 葉芬 于 7-11-2009 05:33 PM 编辑 ]

葉芬

原帖由 kelvin234 于 7-11-2009 03:36 AM 发表
超过1.20了...应该不少人赚到吧.芬姐赚多少??

我的本錢是1.50左右。
最近股價跌有加碼的及先賣後買回賺副不錯。

chan88

用CIMB-GK，如何先卖后买？谢谢。

葉芬

原帖由 chan88 于 7-11-2009 01:55 PM 发表
用CIMB-GK，如何先卖后买？谢谢。

有票在手就能先賣後買回。

chan88

如无票，可卖空后买回吗？

葉芬

原帖由 chan88 于 7-11-2009 05:55 PM 发表
如无票，可卖空后买回吗？

不能。 System不允許。
之前是可以的，最近才實行不能Short Sell。

m.i.k.e

将会有消息公布的一些医药股 : CADX, GENZ, DSCO, JAV, AIKS, AZN, AEMD, MDT, CERS, EXEL, NGSX.......etc (还有十个只.)

请大家好好研究和分享,不要错过赚取高回酬的机会......

葉芬

原帖由 m.i.k.e 于 8-11-2009 09:33 AM 发表
将会有消息公布的一些医药股 : CADX, GENZ, DSCO, JAV, AIKS, AZN, AEMD, MDT, CERS, EXEL, NGSX.......etc (还有十个只.)

请大家好好研究和分享,不要错过赚取高回酬的机会......

嘩 這樣多好東西，那不是要房貸來買了？?

葉芬

9/11/09


CEL-SCI Corp. (CVM) - CVM stock jumped Friday after the company started a clinical trial for H1N1. The stock closed over the 10 day moving average and is testing the 50 day moving average ( $1.27-$1.28 ). A close over the 50 day moving average would be a bullish technical signal and I believe there will be further upside. I would be a seller of a close back below $1.20.

kelvin234

是不是和这新闻有关?

美國‧奧巴馬勝利重要一步‧通過醫療改革方案
（美國‧華盛頓）美國眾議院週六（11月7日）晚以微差票數，通過歷史性的醫療改革法案，令總統奧巴馬的醫改計劃向前邁進重要一步，被視為奧巴馬的內政重要勝利。
經過長達12小時的激烈辯論以及奧巴馬的努力遊說後，眾議院以220對215票，通過這項醫改法案，較所需的票數僅多2票。
微差票數通過
當地時間週六晚上11時零7分（大馬時間約今日（週日，11月8日）中午12時零7分），當議案獲得眾議院通過所需的第218票時，民主黨議員紛紛歡呼和鼓掌；當議長正式宣佈議案通過時，議員們更是發出震耳欲聾的勝利歡呼聲。
不過，法案尚須爭取國會參議院的通過，預計參議院會在數天內，展開有關辯論。
10年9000億美元醫療計劃
這是美國40年來對國內醫療制度進行的最大改革，預計在10年內將耗資9000億美元擴大醫療輔助計劃，包括將3600萬名目前沒有醫療保險的美國人將被納入醫保。
奧巴馬在眾院通過法案後立即發表聲明表示感謝，並稱自己有絕對信心，參院將會跟進通過此法案。
此前，奧巴馬罕有地親赴國會向民主黨議員展開遊說，並透過公開演講強調醫改重要性，但仍有39名民主黨議員，與176名共和黨議員對此項議案投反對票。
有一名共和黨議員破除黨籍界線，投贊成票，印證了奧巴馬爭取兩黨支持的誓言。
事實上，法案在參議院仍然面對阻力，參院的共和黨員已表明會一致投反對票；部份民主黨議員亦反對方案，因此議案能否通過仍不得而知。

葉芬

D.C. Vaccine Conference Attracts Government Policy Makers and Key Biotech Developers

On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC. Investors should keep an eye on this event, which serves as a one-stop destination for valuable updates and exposure on all aspects of vaccine research, development, regulations, and policy via key, intimate presentations by innovative biotech companies and government regulators.
Organizers aim to provide exposure to all avenues of vaccine research, development, regulations and policy and updates on the flu pandemic, bio-defense policy. The National Vaccine Plan will also be addressed and discussed.

Several government officials, including representatives from the United States Department of Health and Human Services, National Research Council of Canada, National Institutes of Health, National Institute of Allergy and Infectious Disease, and the Food and Drug Administration, come together at this conference with with representatives from several key biotech and pharmaceutical companies to provide a first-hand reference of the current U.S. vaccines policy and regulations and updates on pandemic and bio-defense policies.

Attendees will gather to discuss the most recent advancements in novel vaccines designed to target infectious disease like Influenza and AIDS, and will also attempt to gain ideas to use vaccines to target non-infectious diseases such as cancer and allergies.

"The research and discovery of vaccines to fight globally prevalent diseases has been a major focus of the pharmaceutical industry’s biggest players for decades," say members of the conference's organizing committee. "The pharmaceutical world has recently been rocked by the pending expiration of patents on several major block-buster drugs. How does this affect funding for vaccine research and development? What will be the path forward? How will the generic drug industry affect the vaccines market? These are just a few of the questions the Vaccines conference will address and answer."

Scheduled to present the event's opening remarks and to moderate several of the key presentation sessions is Dr.Daniel Zimmerman, Ph.D., (recently interviewed exclusively by BioMedReports), Senior Vice President Research and Development, Cellular Immunology for CEL-SCI Corporation (AMEXVM). Zimmerman's work at the company and in partnership with several research university partners has been attracting a great deal of attention in both the H1N1 influenza and inflammatory disease space lately.

Companies who will share the spotlight in front of some of the key officials from the government agencies include:

Ibis Biosciences, Inc.- In January of this year, this former subsidiary of Isis Pharmaceuticals, Inc. was acquired by Abbott (NYSE: ABT) for a total acquisition price of $215 million plus earn out payments.. The company develops, manufactures, and markets products for the identification and characterization of infectious agents.

Immunovaccine, Inc. (CVEMV) a biotechnology company developing high potential vaccines for human health. Immunovaccine’s most advanced product is DPX-0907, a therapeutic vaccine against ovarian, breast and prostate cancer that, in conjunction with its vaccine delivery technology, is being readied to enter Phase 1 human clinical trials. The company will pursue a fast-track regulatory strategy by taking the product through a short Phase 1 into a Phase 2 clinical trial. In June, the company announced its intention to go public through an RTO transaction on the TSX-V exchange and with FDA approval for Phase I human clinical trial for ovarian, breast and prostate cancer vaccine to begin Q1 2010.

Advaxis, Inc. (OTC:ADXS) a biotechnology company that uses a bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer, infectious disease or allergic syndromes. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression. Preliminary results in humans have shown this technology to be safe, and the therapeutic outcomes are very encouraging. Advaxis is developing multiple platform approaches to the treatment of several cancers which represent a market potential in excess of $10 billion.

EpiVax, a privately held company based in Providence, RI. dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry.

VaxArt, a privately held biotech company based in San Francisco, CA.

VaxDesign, a privately held biotech company based in Orlando, FL that develops in vitro models of human immunity that are functionally equivalent to the human immune system. The technologies help drug and vaccine development companies to obtain predictions of human outcomes for their therapies and have the potential to save companies years of development time and millions of dollars of development costs.

At least three big pharmaceutical companies will also have representatives in attendance, including Novartis (NYSE:NVS), Sanofi Pasteur, and Merck (NYSE:MRK).

Representatives from the academic research field will include:

Dr. Kenneth S. Rosenthal, Ph.D., ProfessorMicrobiology/Immunology, Northeastern Ohio Universities Colleges of Medicine and Pharmacy

Pirouz Daftarian, Head, Biological Modifiers Laboratory, University of Miami

m.i.k.e

http://www.biobusiness.tv/videos/107

http://www.biobusiness.tv/videos/106

m.i.k.e

原帖由 kelvin234 于 9-11-2009 12:27 AM 发表
是不是和这新闻有关?

美國‧奧巴馬勝利重要一步‧通過醫療改革方案
（美國‧華盛頓）美國眾議院週六（11月7日）晚以微差票數，通過歷史性的醫療改革法案，令總統奧巴馬的醫改計劃向前邁進重要一步 ...

没有关系.............

雨若情

幸好有叶芬
不然几天不在都不知道cvm怎样了
叶芬 辛苦你咯